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MISUSE OF BLOOD
To the Editor: In recent months an increasing number of
patients have been referred to us by doctors from outside
with a standard note: ' breathlessness ... tiredness
anaemia (4 - 8 g/IOO mJ) blood transfusion given ..
Hb now 12 g/IOO ml please see and treat'. Many of
these patients have required urgent blood-leiting and dialysis
for iatrogenic pulmonary oedema and renal failure.
Few doctors realize the many disadvantages of, and the
limited indications for, blood transfusion. The disadvantages
are: (i) infection - thrombophlebitis, hepatitis, etc. (ii) allergy,
including renal shutdown; (iii) incompatibility reactions, in-
cluding renal shutdown; (iv) sensitization, making future
transfusions or transplants difficult; (v) volume overload and
cardiac failure; (vi) worsening of uraemia; (vii) limited availa-
bility and enormous cost (R16 - R20 per unit); and (most
important) (viii) delay and confusion in diagnosis and treat-
ment of the cause of the anaemia.
Management of Anaemia
Acute haemorrhage (e.g. obstetric, acute haemolysis, trauma,
gut): Packed cells only should be given, to keep the Hb at
8 - 10 g/IOO mI (haematocrit ± 30%), or above 12 g/IOO ml in
pregnancy. In massive, ongoing haemorrhage, fresh whole
blood should be given after 6 units of packed cells.
Chronic bleeding (e.g. slow gut losses, menorrhagia) or
anaemia of any other cause: Blood transfusion is contra-
indicated, except (a) for urgent anaesthetic - transfuse to
Hb 8 g/IOO ml; (b) if Hb is below ±4 g/lOO ml or if there is
frank high-output cardiac failure or cardiac or brain
i chaemia - 1 - 2 units only; (c) in severe trauma or sepsis
- transfuse to Hb 8 - IO g/I 00 ml wi th packed cells.
For example, the majority of anaemic patients require only
iron replacement (oral, rarely intravenous) for chronic bleed-
ing or frank iron deficiency; folic acid or vitamin B" for
macrocytic anaemia; rarely, steroids for ongoing haemolysis;
and diagnosis and treatment of other causative disease, e.g.
infection, renal failure, cancer, leukaemia.
In patients without obvious bleeding, a blood smear will
how hypochromic microcytic anaemia in most - in which
case only iron replacement is needed. Other anaemic patients
or those without an obvious cause should have a bone marrow
examination and blood urea estimation done.
o patient should have blood transfusion without regular
checking of the urine, blood electrolytes and urea (Azostix is
better than nothing). Diuretics should nor be given routinely.
Although the Hb may rise by only I g/IOO mI per week,
replacement of deficient iron, folate or vitamin B", etc., pro-
duces dramatic symptomatic improvement within a few hours.
N. D. Burman
Renal Unit
Department of Medicine
Tygerberg Hospital and
University of SteIlenbosch
ParowvaIlei, CP
ASSOCIATION OF LACTIC ACIDOSIS WITH
BIGUANIDE THERAPY
To the Editor: I write to endorse the views expressed by Drs
Botha, Vinik and Jackson' that it is not possible to predict
which patients with uncomplicated diabetes are likely to
develop lactic acidosis on biguanide therapy. I should like
to reiterate the point they made, that all biguanides im-
pair lactate clearance and are contraindicated in patients
with renal, cardiac and hepatic insufficiency. I should, how-
ever, also like to emphasize (in the light of their preamble,
'it would be useful if one or another of the biguanides
proved to be free of this ... lactic acidosis . . . complica-
tion'), that all 3 of the biguanides in current therapeutic use
have been shown to be associated with lactic acidosis.'·3
While in no way implying that the authors meant anything
but this, it is imperative that the prescribing doctor is left
in no doubt of this risk with all 3 agents. Until such time
as the relative risk from each of the 3 drugs is known, it
is preferable not to refer to any particular agent as the
'drug of choice', since this connotation is bound to instil a
false sense of security in the prescriber.
The key to the safe use of biguanides today is meticulous
attention to detail, with exclusion of patients in whom
contraindications are known to exist, and close surveillance
of those in whom complications and contraindications might
arise. Anything less might well lead to a spate of cases of
lactic acidosis from the indiscriminate use of the currently
favoured biguanides (and there are those who favour met-
formin'), and precipitate a ban on the use of all these agents.
A. C. Asmal
Acting Head of Departmenr
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HYCANTHONE - A DANGER ASSOCIATED WITH
ITS USE
To the Editor: I should like to draw the attention of your
readers, especially those in peripheral hospitals, to a recent
fatality in a patient treated with hycanthone. Full details of
this report will be published at a later date.
Suffice it to say at the present that this patient received an
appropriate dose of hycanthone, and became jaundiced and
restless. Promethazine hydrochloride was administered, but
coma ensued and the child died 2 days later. Autopsy revealed
features of acute massive hepatic necrosis.
As stated by Gane,' hycanthone is contraindicated in
patients who have concurrent infections, or who have been ill
in the past month, or have known or suspected liver damage,
or are receiving hepatotoxic drugs. The use of chlorpromazine
in conjunction with hycanthone is specifically contraindicated.
We should be grateful for further details of any cases in
which hycantbone may have been a contributing factor to a
patient's death, such as for example the report by KaIJmeyer
er al.'
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ERRATUM
In the article entitled 'Autopsy findings in mental patients',
by Gillian Cole, on page 534 of the SAMJ of 17 September
1977, the second sentence of the second paragraph under the
subheading 'Subdural Haematoma' on page 535 ought to
have been omitted. It read as folJows: 'In the remaining 3
cases the diagnosis was not made, nor was there sufficient
time to make it.'
